Proteomic profiling of precipitated Clostridioides difficile toxin A and B antibodies

被引:2
|
作者
Adamson, Penelope J. [1 ,2 ]
Wang, Jing J. [2 ,3 ]
Anosova, Natalie G. [4 ]
Colella, Alex D. [5 ]
Chataway, Timothy K. [5 ]
Kleanthous, Harry [4 ]
Gordon, Tom P. [2 ,3 ]
Gordon, David L. [1 ,2 ]
机构
[1] Flinders Univ S Australia, Dept Microbiol & Infect Dis, Bedford Pk, SA 5042, Australia
[2] SA Pathol, Flinders Med Ctr, Bedford Pk, SA 5042, Australia
[3] Flinders Univ S Australia, Dept Immunol, Bedford Pk, SA 5042, Australia
[4] Sanofi Pasteur, Cambridge, MA USA
[5] Flinders Univ S Australia, Flinders Med Ctr, Flinders Prote Facil, Bedford Pk, SA 5042, Australia
基金
英国医学研究理事会;
关键词
C; difficile; Vaccination; Serum antibody repertoire; Proteomics; Mass spectrometric sequencing; AUTOANTIBODY PROTEOMES; SJOGRENS-SYNDROME; INFECTION; EPIDEMIOLOGY; CANDIDATE; DISEASE; BEZLOTOXUMAB; PROTECTION; DIAGNOSIS; VACCINE;
D O I
10.1016/j.vaccine.2019.10.096
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Clostridioides difficile infection is the leading cause of nosocomial diarrhoea globally. Immune responses to toxins produced by C. difficile are important in disease progression and outcome. Here, we analysed the anti-toxin A and anti-toxin B serum antibody proteomes following natural infection or vaccination with a C. difficile toxoid A/toxoid B vaccine using a modified miniaturised proteomic approach based on de novo mass spectrometric sequencing. Analysis of immunoglobulin variable region (IgV) subfamily expression in immunoprecipitated toxin A and toxin B antibodies from four and seven participants of a vaccine trial, respectively, revealed a polyclonal proteome with restricted IGHV, IGKV and IGLV subfamily usage. No dominant IGHV subfamily was observed in the toxin A response, however the dominant anti-toxin B heavy (H)-chain was encoded by IGHV3-23. Light (L)-chain usage was convergent for both anti-toxin A and anti-toxin B proteomes with IGKV3-11, 3-15, 3-20 and 4-1 shared among all subjects in both cohorts. Peptide mapping of common IgV families showed extensive public and private amino acid substitutions. The cohort responses to toxin A and toxin B showed limited similarity in shared IGHV subfamilies. L-chain subfamily usage was more similar in the anti-toxin A and anti-toxin B responses, however the mutational signatures for each subfamily were toxin-dependent. Samples taken both post vaccination (n = 5) or at baseline, indicating previous exposure (n = 2), showed similar anti-toxin B IgV subfamily usage and mutational profiles. In summary, this study provides the first sequence-based proteomic analysis of the antibody response to the major disease-mediating toxins of C difficile, toxin A and toxin B, and demonstrates that despite the potential for extreme diversity, the immunoglobulin repertoire can raise convergent responses to specific pathogens whether through natural infection or following vaccination. (C) 2019 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:2077 / 2087
页数:11
相关论文
共 50 条
  • [41] Proteomic Adaptation of Clostridioides difficile to Treatment with the Antimicrobial Peptide Nisin
    Maass, Sandra
    Bartel, Jurgen
    Muecke, Pierre-Alexander
    Schlueter, Rabea
    Sura, Thomas
    Zaschke-Kriesche, Julia
    Smits, Sander H. J.
    Becher, Dorte
    CELLS, 2021, 10 (02) : 1 - 21
  • [42] Cytotoxic synergism of Clostridioides difficile toxin B with proinflammatory cytokines in subjects with inflammatory bowel diseases
    Gabrio Bassotti
    Alessandro Fruganti
    Fabrizio Stracci
    Pierfrancesco Marconi
    Katia Fettucciari
    World Journal of Gastroenterology, 2023, 29 (04) : 582 - 596
  • [43] Comparative Evaluation of Three Immunoassays for the Simultaneous Detection of Clostridioides difficile Glutamate Dehydrogenase and Toxin A/B
    Kim, Namsu
    Lee, Seung Yeob
    Park, Joonhong
    Lee, Jaehyeon
    MICROORGANISMS, 2022, 10 (05)
  • [44] Cytotoxic synergism of Clostridioides difficile toxin B with proinflammatory cytokines in subjects with inflammatory bowel diseases
    Bassotti, Gabrio
    Fruganti, Alessandro
    Stracci, Fabrizio
    Marconi, Pierfrancesco
    Fettucciari, Katia
    WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (04) : 582 - 596
  • [45] In Vivo Physiological and Transcriptional Profiling Reveals Host Responses to Clostridium difficile Toxin A and Toxin B
    D'Auria, Kevin M.
    Kolling, Glynis L.
    Donato, Gina M.
    Warren, Cirle A.
    Gray, Mary C.
    Hewlett, Erik L.
    Papin, Jason A.
    INFECTION AND IMMUNITY, 2013, 81 (10) : 3814 - 3824
  • [46] Clostridioides difficile Toxin B PCR Cycle Threshold as a Predictor of Toxin Testing in Stool Specimens from Hospitalized Adults
    Lee, Sean
    Nanda, Neha
    Yamaguchi, Kenichiro
    Lee, Yelim
    She, Rosemary C.
    ANTIBIOTICS-BASEL, 2022, 11 (05):
  • [47] Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence
    Gupta, Swati B.
    Mehta, Vinay
    Dubberke, Erik R.
    Zhao, Xuemei
    Dorr, Mary Beth
    Guris, Dalya
    Molrine, Deborah
    Leney, Mark
    Miller, Mark
    Dupin, Marilyne
    Mast, T. Christopher
    CLINICAL INFECTIOUS DISEASES, 2016, 63 (06) : 730 - 734
  • [48] Impact of deoxycholate on Clostridioides difficile growth, toxin production, and sporulation
    Usui, Yukino
    Ayibieke, Alafate
    Kamiichi, Yuko
    Okugawa, Shu
    Moriya, Kyoji
    Tohda, Shuji
    Saito, Ryoichi
    HELIYON, 2020, 6 (04)
  • [49] EPIDEMIOLOGY OF CLOSTRIDIOIDES DIFFICILE TOXIN POSITIVE PATIENTS IN A TERTIARY CENTRE
    Franklin, James
    Lewis, Nina
    GUT, 2022, 71 : A160 - A160
  • [50] RstA Is a Major Regulator of Clostridioides difficile Toxin Production and Motility
    Edwards, Adrianne N.
    Anjuwon-Foster, Brandon R.
    McBride, Shonna M.
    MBIO, 2019, 10 (02):